This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.

Disclosed herein is a method for identifying and treating a Streptococcus pyogenes (group A Streptococcus, GAS) infection in a subject. The method mainly includes determining the presence of endopeptidase O (PepO) protein in the biological sample; and administering an effective amount of an anti-infective agent to the subject to ameliorate symptoms associated with the GAS infection if the PepO protein is present in the biological sample.

The disclosure, in some aspects, provides a composition comprising labelled and/or tagged and/or bound amino acid sequences useful for the detection of Babesia species. Also disclosed are methods for the detection of infection by one or more Babesia species.

The present invention relates to methods for identifying high molecular mass lipids in samples. Such high molecular mass lipids may be useful as biomarkers for the identification of disease.

The present disclosure is directed to antibodies binding to and neutralizing dengue virus and methods for use thereof.

The present invention refers to an in vitro method for obtaining clinical data in patients suffering from an inflammatory disease, preferably, for predicting mortality risk among patients suffering from sepsis or for deciding whether to administer a medical treatment to a patient suffering from an autoinflammatory syndrome.

The present invention provides isolated monoclonal antibodies, or antigen-binding portions thereof, that bind to ZIKV glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies, or antigen-binding portions thereof, according to the present invention are useful for inhibiting or neutralizing ZIKV activity, thus providing a means of treating or preventing ZIKV infection in humans. The antibodies, or antigen-binding portions thereof, according to the present invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

A collection device for a biological sample to capture target compounds such as viruses or other pathogens or particles for testing from within the sample and move the captured target compound to a separate chamber for subsequent processing. The collection device can include an openable substance blister including capture particles located in a cup interior. Capture particles can attract and bind the target compounds from the sample. An extraction tube extracts any nucleic acid from the target compound for storage or subsequent amplification and testing to confirm presence of known microorganisms. The extraction tube can comprise a heat-deformable material and can be connected to a microfluidic cartridge for further processing of nucleic acid including, amplification and detection. The microfluidic cartridge includes valves and a plurality of chambers for amplification.

Provided herein is technology relating to treating septic shock and particularly, but not exclusively, to methods and systems for identifying sepsis patients most likely to benefit from L-carnitine treatment.

The invention mainly relates to the mass spectrometric identification of pathogens in blood cultures from bloodstream infections (septicemia). The invention provides a method with which microbial pathogens can be separated in purified form from blood after a relatively brief cultivation in a blood culture flask, without any interfering human proteins or any residual fractions of blood particles such as erythrocytes and leukocytes, and can be directly identified by mass spectrometric measurement of their protein profiles. The method is based on the use of relatively strong tensides to destroy the blood particles by dissolving the weak cell membranes and most of the internal structures of the blood particles; in spite of the fact that tensides are regarded as strong ionization inhibitors in MALDI and other ionization processes required for mass spectrometric measurements. This method allows unknown pathogens to be obtained in their pure form by centrifuging or filtration and to be identified on the taxonomic level of species or subspecies. Problems with DNA from high levels of leukocytes can be resolved by special measures. After sufficient cultivation, the identification in a mass spectrometric laboratory takes only half an hour.